Our faculty members are subspecialty-trained, board-certified hematologists and oncologists who care for inpatients at UCI Medical Center and outpatients at Chao Family Comprehensive Cancer Center, which is the only National Cancer Institute-designated comprehensive cancer center in Orange County and one of only 50 in the nation. For more information, call us at 714-456-8000 or fill out an appointment request form Individual Treatment Plans Fellows receive a thorough grounding in general hematology, hematologic malignancy and solid tumors. At the UCI Chao Family Comprehensive Cancer Center, we work to prevent, manage, and cure cancer so all people live healthier, longer lives. COVID-19 vaccine and protecting your health , UCI Health Chao Family Comprehensive Cancer Center, only adult hematopoietic stem-cell transplant services, HIPEC, or hyperthermic intraoperative peritoneal chemotherapy, Take a virtual tour of the infusion center at UCI Health Cancer Center Newport , OCMA honors UCI Health 'Physicians of Excellence', 2022 UCI Anti-Cancer Challenge raises record $1 million for promising cancer research, UCI opens first natural killer cell clinical trial for recurrent glioblastoma, UCI Health among Americas Best Hospitals for 22nd consecutive year, UCI Health renewed as Orange Countys only federally designated comprehensive cancer center, Gastric cancer patient gets new lease on life, A novel approach to advanced stomach cancer, Beating the odds: Help for advanced gastrointestinal cancers, Eye Care Services | Gavin Herbert Eye Institute, Neonatal Intensive Care Unit Services (NICU), Occupational & Environmental Health Services, Parkinson's Disease and Movement Disorders Program, Pediatric Endocrinology and Diabetes Services, Physical Medicine and Rehabilitation Services, Comprehensive Stroke & Cerebrovascular Center, Susan Samueli Integrative Health Institute, Center for Urological Care | UCI Health Urology Services, Vascular Birthmarks & Malformations Diagnostic and Treatment Center. For questions about the application process, go to ERAS online or call 215.966.3940. For example, radiation or chemotherapy may be used to shrink a tumor before surgery. We work closely with you and your family to discuss potential treatment options and encourage questions. The Division of Hematology/Oncology at the UCI School of Medicine's Department of Medicine is dedicated to education, research and state-of-the-art care of patients with blood diseases and cancer. Research is conducted under the supervision of the research mentor and the research oversight committee. This recognition reflects our expertise in translating leading-edge scientific findings into clinical cancer treatment on all levels. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Latest version (submitted February 28, 2023) on ClinicalTrials.gov A study version is represented by a row in the table. We are engaged in basic and translational cancer research to better understand cancer and blood diseases and also to use the best, leading-edge clinical approaches for our patients. 15th Annual Hematologic Malignancies Demystified Unraveling the Challenges of Diagnosis and Treatment in Malignant Hematology. Candidates must be a U.S. citizen, permanent resident orhold a J-1 visa with ECFMG sponsorshipat the time of application submission. Hematology-Oncology MyChart patient portal offers a convenient and secure way to manage your healthcare online. Research The Division of Hematology/Oncology at the UCI School of Medicine's Department of Medicine offers a rigorous three-year accredited fellowship program that emphasizes intensive theoretical training and a broad spectrum of clinical experience with the goal of preparing highly skilled hematologists and oncologists for careers in both clinical and Dr. Chao Shuo Huang, MD . of complications from the coronavirus because of their compromised immune systems. Therefore, understanding how to induce mucosal immune responses in piglets is essential in the mechanism and application against PEDV infection with mucosal immunity. Home. UC Irvine Health 200 S. Manchester Ave. Suite 400, Room 417 . Predefined criteria were used to. We also offer the only adult hematopoietic stem-cell transplant services in Orange County, which means that patients with leukemia, lymphoma and other cancers no longer need to travel long distances for this life-saving treatment. Dr. Stefan O. Ciurea is a UCI Health hematologist and director of the Hematopoietic Stem Cell Transplantation and Cellular Therapy Program at the Chao Family Comprehensive Cancer Center. The UC Hematologic Malignancies & Bone Marrow Transplant Center offers the most advanced care in the region for adults with cancers of the blood. Professor of Clinical Medicine, Hematology/Oncology. The University of California, Irvine, School of Medicine, Department of Medicine, Division of Hematology/Oncology is seeking a dynamic leader with strong credentials in clinical medicine and basic, translational, or clinical research for the position of Hematology/Oncology Division Chief. The UCI/CHOC PHO Fellowship Program is a 3-year ACGME accredited fellowship program that aims to educate the future generation of leaders, researchers, and clinical physicians in the field of pediatric hematology & oncology. A method of treatment in our research was used to make an oral vaccine that packaged the inactive PEDV . Some of our clinical research is focused on prevention of breast, colon, esophageal, liver, pancreatic and prostate cancers, in both phase 2 and phase 3 clinical trials, as well as phase 1 trials. The three-year program is approved by the Accreditation Council for Graduate Medical Education (ACGME) and is recognized by the American Board of Internal Medicine (ABIM). University of California, Irvine Irvine, CA 92697, The Division of Hematology/ Oncology is actively recruiting for clinical faculty , Elizabeth Brem, MD, on Which CLL Abstract From ASH 2022 Cant Be Ignored, Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study - Dr. Helen Ma, Treatment Options for Patients With Relapsed/Refractory FL, Dr. Frank Meyskens received the prestigious foundation award for humanitarianism. Our cancer experts also are available to provide second opinions At the cancer center, you are cared for by a world-class team of cancer specialists, including medical oncologists, surgeons, radiation oncologists and pathologists, as well as highly trained nurses, rehabilitation therapists, pharmacists, social workers and dietitians. Clinical Professor, Division of Hematology/Oncology, Medicine School of Medicine Associate Director for Clinical Sciences, Chao Family Comprehensive Cancer Center M.D., Chicago Medical School, 1986, Medicine B.S., University of Southern California, 1981, Psychobiology Phone: (714) 456-5153 Fax: (714) 456-2242 Email:
[email protected] COVID-19 vaccine and protecting your health , only adult hematopoietic stem-cell transplant services, Quality OncologyPractice Initiative (QOPI) CertificationProgram, complete our online appointment request form , adult stem cell transplant and cellular therapy program, Take a virtual tour of the infusion center at UCI Health Cancer Center Newport , A novel approach to advanced stomach cancer, Beating the odds: Help for advanced gastrointestinal cancers, OCMA honors UCI Health 'Physicians of Excellence', 2022 UCI Anti-Cancer Challenge raises record $1 million for promising cancer research, UCI opens first natural killer cell clinical trial for recurrent glioblastoma, Breast cancer early diagnosis and treatment, Integrative and alternative cancer therapies, Phase I and phase II trials of novel drugs. If you are not already licensed in the state, contact the Medical Board of California at 1426 Howe Ave., Suite 54, Sacramento, CA 95825-3236. During the second and/or third year fellows develop and participate in a longitudinal research project spanning 18 months of protected time under the supervision of research mentor. Read More . Management of Metastatic Colorectal Cancer in the Community-Based Setting. Access MyChart Overview Education Bio Locations Medical Services Lung Cancer Services Medical Oncology Services Contact. UCI Health medical oncologists are at the forefront of cancer treatment with chemotherapeutic drugs, biological agents and therapies that work with the patients immune system. Telephone consultation is available 24 hours a day. In some cases, patients may undergo treatment to reduce a tumor prior to surgery, an approach shown to improve survival and lower the rate of recurrence for some cancers. Our cancer experts also are available to provide second opinions , To make an appointment, call 714-456-8000 or submit an online request , Learn about UCI Health COVID-19 safety measures (video) . 855-211-3729. UCI Health hematologic oncologists provide expert consultation and treatment for patients with many different types of cancer. Ciurea earned his medical degree at Grigore T. Popa University of Medicine and Pharmaceuticals in Iasi, Romania. Learn more about our research and clinical trials . Here at UCI Department of Medicine, we highly value diversity. For more information, please contact us at
[email protected] or 877-827-8839. Elizabeth Brem, MD, on Frontline Management of CLL, UCI and CSU Fullerton partner to advance cancer health disparities research with a focus on diversity and inclusion, Virus-based sensor detects bladder cancer markers in urine, 200 S. Manchester Drive, Orange, CA 92868-3217, General Medical Appointments: 714-456-8000, Biotechnology, Imaging & Drug Development, Stern Center for Cancer Clinical Trials and Research, Acknowledgement of Grant and Shared Resources, Anti-Cancer Challenge Pilot Research Projects, CSUF/UCI-CFCCC Cancer Health Equity Research Partnership (CHERP), UCI Susan & Henry Samueli College of Health Sciences. Patients who were older than 18 years of age and met the criteria of sudden hearing loss without an identifiable etiology were . We are participating in a National Cancer Institute clinical trial to determine whether COVID-19 affects therapies in cancer patients who acquire the virus. The fellowship program is designed to educate and support future clinical investigators who plan to dedicate their professional careers to clinical or laboratory research in hematology and oncology. During the second half of the first year fellows begin exploring research options around their individual interests. Fellows' List of Research Publications 2010-2018 (fellows names appear in bold), Associate Program Director Lisa X. Lee, MD, Associate Program Diorectr Ann Eapen, MD, Research Rotation Director Angela Fleischman, MD, PhD, Division Chief: Edward L. Nelson, MD, FACP, Christopher SongEducation Programs Assistant AnalystPhone: 714-456-6589Fax: 714-456-2242E-mail:
[email protected], The Division of Hematology/OncologyUCI Medical Center101 The City Drive SouthBuilding 56, Room 239, ZOT 4061Orange, CA 92868, University of California, Irvine Irvine, CA 92697, Accreditation Council for Graduate Medical Education (ACGME), American Board of Internal Medicine (ABIM), Educational Commission for Foreign Medical Graduates (ECFMG), Electronic Residency Application Service (ERAS), A novel method for demonstrating cold agglutinin disease: a case report, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905110/, Secondary hemophagocytic lymphohistiocytosis in the setting of metastatic renal cell carcinoma: a case report, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333406/, PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533281/, Prostatic Lymphoma Masquerading as Urinary Retention and Hematuria With Review of Literature, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650011/, http://pancreas.imedpub.com/pancreatic-neuroendocrine-tumors-therapy.pdf, Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia, https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=4&p_RefId=2737934, Treatment of pregnancy associated metastatic hormone and Her-2 receptor positive inflammatory breast cancer: A real challenge, https://doi.org/10.1016/j.ctarc.2016.09.003, https://www.sciencedirect.com/science/article/pii/S2468294216300739, Deadly Portland Cement: The Triad of Pulmonary, Dermatologic and Hematological Manifestations, https://www.sciencedirect.com/science/article/pii/S0002962916301379?via%3Dihub, BRAFV600E Mutations in High Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008024/, Primary Hepatic Osteosarcoma: A Rare Cause of Primary Liver Tumor, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827792/. Oversees and is responsible for the adherence of the technical staff to these SOPs and original work. The hematology division provides diagnostic, therapeutic and consultative care to children with hematologic disorders such as hemophilia, anemia and platelet disorders. Teaching Award, Hematology/Oncology Fellowship Program, University of . With the rapid development of mobile positioning technologies, location-based services (LBSs) have become more widely used. These divisions host a Hematology/Oncology fellowship program. For graduates of medical schools outside the United States, please note that the licensure process can take six to 12 months or longer. People who are undergoing or have recently had chemotherapy are at high risk
http://www.avensonline.org/fulltextarticles/jun-2380-0585-02-0009.html, Obstructive Jaundice as Initial Presentation of Multiple Myeloma: Case Presentation and Literature Review, https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/26221143/, I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib, https://www.sciencedirect.com/science/article/pii/S0169500215000938?via%3Dihub, Pancytopenia in a patient with cystinosis secondary to myelosuppression from cystine crystal deposition: a case report, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573917/, Patients' preferences for biopsy result notification in an era of electronic messaging methods, https://jamanetwork.com/journals/jamadermatology/fullarticle/2212245, Assessing Bacterial Isolates in Bloodstream Infections and Trend of the Antimicrobial Resistance in the Hematological and Solid Malignancies, http://www.bloodjournal.org/content/126/23/5628/tab-article-info, Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254519/, Mammalian Y chromosomes retain widely expressed dosage-sensitive regulators, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139287/, The case of the missed physical examination: testicular carcinoma presenting as a GI bleed, http://ascopubs.org/doi/abs/10.1200/JCO.2012.45.2680?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed, Mortality risk after preoperative versus postoperative chemotherapy and radiotherapy in lymph node-positive rectal cancer, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551443/, Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593948/, Heart rate decrease during crizotinib treatment and potential correlation to clinical response, Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593561/, Excessive therapeutic response in a case of blastic plasmacytoid dendritic cell neoplasm, Population-based evaluation of adenosquamous carcinoma of the colon and rectum, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330249/, Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy, https://www.futuremedicine.com/doi/full/10.2217/fon.12.25?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&, Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443348/, New mechanistic explanation for the localization of ulcers in the rat duodenum: Role of iron and selective uptake of cysteamine, https://www.sciencedirect.com/science/article/pii/S0003986112002135?via%3Dihub, Meat consumption, ornithine decarboxylase gene polymorphism, and outcomes after colorectal cancer diagnosis, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516190/, Risk of second primary colorectal cancer among colorectal cancer cases: a population-based analysis, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072650/, Timing of radiation therapy, lymph node retrieval, and survival in rectal cancer, https://insights.ovid.com/pubmed?pmid=21471752, Oligohydramnios associated with administration of weekly paclitaxel for triple-negative breast cancer during pregnancy, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202168/, Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140277/, Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017764/, Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles, https://www.spandidos-publications.com/ijmm/26/1/121, Target of rapamycin signaling in leukemia and lymphoma, http://clincancerres.aacrjournals.org/content/16/22/5374.long, Board-certification or board-eligibility in internal medicine, Proof of medical school graduation (original diploma), Proof of passing the three-step United States Medical Licensing Examination (USMLE), U.S. citizenship, permanent residency, or J-1 visa with ECFMG sponsorship.